These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

AstraZeneca PLC AZN

• Dividend Yield: 3.00%
• Argus Research analyst Jasper Hellweg maintained a Buy rating and cut the price target from $85 to $80 on May 26, 2023. This analyst has an accuracy rate of 66%.
• SVB Leerink analyst Andrew Berens maintained an Outperform rating and raised the price target from $78 to $79 on Nov. 14, 2022. This analyst has an accuracy rate of 55%.
• Recent News: AstraZeneca reported topline results from the TROPION-Lung01 phase 3 trial of datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer.

Medtronic plc MDT

• Dividend Yield: 3.19%
• Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $90 to $92 on May 26, 2023. This analyst has an accuracy rate of 80%.
• Wells Fargo analyst Larry Biegelsen upgraded the stock from Equal-Weight to Overweight and raised the price target from $77 to $100 on April 24, 2023. This analyst has an accuracy rate of 77%.
• Recent News: Medtronic presented new clinical and real-world data on the MiniMed 780G system at the 83rd American Diabetes Association Scientific Sessions.

CVS Health Corporation CVS

• Dividend Yield: 3.49%
• Mizuho analyst Ann Hynes maintained a Buy rating and cut the price target from $120 to $88 on July 11, 2023. This analyst has an accuracy rate of 72%.
• Truist Securities analyst David Macdonald maintained a Buy and cut the price target from $109 to $103 on June 20, 2023. This analyst has an accuracy rate of 78%.
• Recent News: CVS Health recently inked an 18-megawatt agreement with Constellation Energy Corporation to buy zero-emission, renewable energy, which will be equivalent to the annual electricity use of its 147 CVS Health locations throughout Michigan.

Read More: AngioDynamics, Disney And 3 Stocks To Watch Heading Into Wednesday